PE Anti-TMEM175 antibody [EPR24415-47],Abcam,AB318400
Patented technology Our RabMAb ® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb ® patents . What are the advantages of a recombinant monoclonal antibody? This product is a recombinant monoclonal antibody, which offers several advantages including: - High batch-to-batch consistency and reproducibility - Improved sensitivity and specificity - Long-term security of supply - Animal-free batch production For more information, read more on recombinant antibodies . How are conjugated primary antibodies validated? This conjugated primary antibody is released using a quantitative quality control method that evaluates binding affinity post-conjugation and efficiency of antibody labeling. For suitable applications and species reactivity, please refer to the unconjugated version of this clone.
Host
Rabbit
Reactivity
Human
Application
Antibody Labelling, Target Binding Affinity, IHC-P
Conjugate
PE
Platform ID
BAB930387666
Abcam
Contact
Tel: +44 (0)1223 696000
Fax: +44 (0)1223 215 215
Email:
Specifications
Scientific Background
Target data Proton-activated proton channel that catalyzes proton efflux from endosomes and lysosomes to maintain a steady-state pH (PubMed : 35333573, PubMed : 35750034, PubMed : 37390818). Activated at low pH (under pH 4.6) by luminal side protons : selectively mediates lysosomal proton release from lysosomes, eliciting a proton leak that balances V-ATPase activity to maintain pH homeostasis (PubMed : 35750034). Regulation of lumenal pH stability is required for autophagosome-lysosome fusion (PubMed : 26317472, PubMed : 32267231). Also acts as a potassium channel at higher pH, regulating potassium conductance in endosomes and lysosomes (PubMed : 26317472, PubMed : 28723891, PubMed : 32228865, PubMed : 32267231, PubMed : 33505021). Constitutes the pore-forming subunit of the lysoK(GF) complex, a complex activated by extracellular growth factors (PubMed : 33505021). The lysoK(GF) complex is composed of TMEM175 and AKT (AKT1, AKT2 or AKT3), a major target of growth factor receptors : in the complex, TMEM175 channel is opened by conformational changes by AKT, leading to its activation (PubMed : 33505021). The lysoK(GF) complex is required to protect neurons against stress-induced damage (PubMed : 33505021). See full target information TMEM175
Category Paths
- Products>Primary Antibodies>Monoclonal Antibodies
- Products>Primary Antibodies>IHC Antibodies
- Products>Primary Antibodies>Recombinant Antibodies
Please provide the required information below so that we can quickly source your products.